Innovent’s Sulinno (Adalimumab biosimilar) Receives China’s NMPA Approval for Pediatric Plaque Psoriasis and Non-infectious Uveitis

December 28, 2020 Auto Bot Biosimilars, Innovent, Receive 0

Shots:

  • The approval is granted in pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults, who do not respond adequately to corticosteroids.
  • These are fifth and sixth approved indications of Sulinno in China and it was first approved by NMPA on Sep 2, 2020
  • Sulinno is an adalimumab biosimilar which is a recombinant human anti-TNF-α mAB developed by Innovent and are indicated in rheumatoid arthritis, ankylosing spondylitis, psoriasis, and polyarticular juvenile idiopathic arthritis.

Click here ­to­ read full press release/ article | Ref: Innovent  | Image: Innovent

The post Innovent’s Sulinno (Adalimumab biosimilar) Receives China’s NMPA Approval for Pediatric Plaque Psoriasis and Non-infectious Uveitis first appeared on PharmaShots.